SOPHiA GENETICS Announces Kepler Uniklinikum is Live on SOPHiA DDM™ Platform

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) has announced that Kepler Uniklinikum, Austria's second largest hospital, has gone live with its SOPHiA DDM™ Platform. The hospital will use this platform to enhance its next-generation sequencing (NGS) testing and diagnostics specifically for blood cancers. Kepler Uniklinikum, housing 1,800 beds, aims to deepen its in-house NGS testing capabilities and expand services for patients with blood cancers and disorders. The SOPHiA DDM™ Platform provides nearly 100% reproducible results, supporting timely, cost-effective, and reliable sequencing data to aid in the rapid and accurate detection of genomic variants. This move is expected to benefit not only the local population but also provide valuable insights to other users of the platform globally.

Positive

• Kepler Uniklinikum, Austria's second largest hospital, adopts SOPHiA DDM™ Platform.
• The platform enhances next-generation sequencing (NGS) testing for blood cancers.
• It supports timely, cost-effective, and reliable sequencing data.
• SOPHiA DDM™ Platform provides nearly 100% reproducible results.
• The implementation expands Kepler Uniklinikum's in-house NGS capabilities.
• Data from the platform can support other users globally.

Negative

• The press release lacks specific financial data indicating direct revenue impact for SOPH.
• No clear information on the costs involved in implementing the SOPHiA DDM™ Platform.

Insights

Medical Research Analyst

Kepler Uniklinikum's adoption of the SOPHiA DDM™ Platform marks a significant step in enhancing diagnostic capabilities for blood cancers. By integrating next-generation sequencing (NGS) in their testing, the hospital can detect genomic variants with greater precision. This advancement is not just about better diagnostics but also about enriched data for global research. NGS technology allows for sequencing of DNA and RNA more quickly and cheaply than traditional methods, making it invaluable in research and clinical practice. For patients, this means faster time to diagnosis and potentially earlier and more targeted treatments.

It's essential to acknowledge that the consistent and nearly 100% reproducibility touted by SOPHiA GENETICS translates to high reliability and trustworthiness in medical data. This is particularly critical for blood cancers, where detecting the right variants can significantly affect treatment choices and outcomes.

From a long-term perspective, the continuous machine learning improvements in the platform may lead to even more precise results over time. For investors, this integration highlights SOPHiA GENETICS' robust presence and potential for growth in the European healthcare market, leveraging data-driven solutions to tackle significant health issues.

Financial Analyst

The announcement that Kepler Uniklinikum is live on the SOPHiA DDM™ Platform is strategically promising for SOPHiA GENETICS. Partnerships with major healthcare institutions bolster the company's market position and can lead to increased revenues. Austria's second-largest hospital adopting their platform indicates strong market acceptance and confidence in their technology.

Investors should note that this could spur further adoption across Europe, especially in regions where cancer diagnosis and treatment are critical public health concerns. Financially, this partnership may help stabilize revenue streams from platform subscriptions and services, enhancing the company's growth trajectory. Additionally, the data generated through this partnership could contribute to further refinements and new offerings, opening up additional revenue channels.

However, it's also essential to consider the competitive landscape. The med-tech industry, especially in genomics, is highly competitive with continuous innovations. SOPHiA GENETICS must maintain and advance its technological edge to capitalize on this momentum.

The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers

BOSTON and ROLLE, Switzerland, June 13, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that Kepler Uniklinikum, Austria's second largest hospital, is live on SOPHiA GENETICS' platform. The hospital will use the SOPHiA DDM™ Platform to advance its next-generation sequencing (NGS) testing and diagnostics of blood-related cancers.

Kepler Uniklinikum, which has 1,800 beds, is the central healthcare provider for Upper Austria. The hospital will implement the SOPHiA DDM™ Platform across its medical and chemical laboratory locations to deepen its in-house NGS testing capabilities and expand its offerings to its patients, specifically for those faced with blood cancers and disorders.

Cancer is the second most common cause of death in Austria, with about 42,000 people diagnosed with cancer each year.¹ Additionally, on a global scale, blood cancers are the fifth most common type of cancer in the world.² Advances in diagnostics and treatment of blood cancers depend on timely, cost-effective, and reliable sequencing data. The SOPHiA DDM™ Platform uses NGS to target key variants from FFPE, blood, or bone marrow samples, helping lead to fast and accurate detection of variants associated with the disease. The SOPHiA DDM™ Platform is specifically designed to compute a wide array of genomic variants and continually hones its machine learning algorithms to detect genomic variants associated with rare and challenging cases.

"Kepler Uniklinikum's implementation of the SOPHiA DDM™ Platform will help progress the use of data-driven medicine throughout Austria by ensuring their patients receive the most advanced and accurate testing," said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. "This testing will not only help the local population but will provide valuable insights and data to support others using the SOPHiA DDM™ Platform around the world."

The SOPHiA DDM™ Platform delivers results that are nearly 100 percent reproducible to provide consistent inter- and intra-run results, ensuring stable and trustworthy sequencing data.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn. 

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA DDM™ for Lymphoid Malignancies is available as a CE-IVD product for In Vitro Diagnostic Use in Europe and Turkey. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

¹ https://ascopost.com/issues/october-25-2022/incidence-and-cancer-related-mortality-in-austria/
² https://www.worldwidecancerresearch.org/news-opinion/2022/september/blood-cancer-everything-you-need-to-know/ 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-kepler-uniklinikum-is-live-on-sophia-ddm-platform-302171344.html

SOURCE SOPHiA GENETICS

FAQ

What is SOPHiA GENETICS' stock symbol?

SOPH.

Why did Kepler Uniklinikum implement the SOPHiA DDM™ Platform?

To enhance NGS testing and diagnostics for blood cancers.

What type of cancer is Kepler Uniklinikum focusing on with the SOPHiA DDM™ Platform?

Blood cancers.

How many beds does Kepler Uniklinikum have?

1,800 beds.

What are the benefits of the SOPHiA DDM™ Platform?

It provides timely, cost-effective, and reliable sequencing data with nearly 100% reproducible results.

When was the announcement about Kepler Uniklinikum going live with SOPHiA DDM™ Platform made?

June 13, 2024.

Where is Kepler Uniklinikum located?

Upper Austria.